Designing Circular Peptide Drugs That Block HIV Protease
Crystal structures of seven macrocyclic peptidomimetics bound to HIV protease reveal how circular peptide scaffolds can achieve potent antiviral activity with improved drug-like properties.
Quick Facts
What This Study Found
High-resolution crystal structures of seven macrocyclic HIV protease inhibitors revealed specific binding interactions, demonstrating how cyclic peptide scaffolds can achieve potent enzyme inhibition with improved drug properties.
Key Numbers
How They Did This
X-ray crystallography study determining high-resolution structures of seven macrocyclic peptidomimetics complexed with HIV-1 protease. Structure-activity analysis correlated binding features with inhibitory potency.
Why This Research Matters
HIV protease inhibitors are a cornerstone of AIDS treatment. Designing cyclic versions with better stability and bioavailability could improve existing drugs and inspire peptidomimetic approaches for other diseases.
The Bigger Picture
The macrocyclic approach to drug design — converting linear peptides into circular ones — is now a major strategy in pharmaceutical development. This study provided early structural proof that this approach works for clinically important targets.
What This Study Doesn't Tell Us
Structural study focused on binding interactions, not clinical pharmacology. In-vitro potency may not predict in-vivo drug performance. Synthesis of macrocyclic compounds can be challenging at scale.
Questions This Raises
- ?Can these macrocyclic designs achieve oral bioavailability?
- ?Could the macrocyclic scaffold approach be applied to other protease targets?
- ?Which ring size and composition optimizes both potency and drug properties?
Trust & Context
- Key Stat:
- 7 structures solved High-resolution crystal structures reveal exactly how macrocyclic peptide drugs bind and inhibit HIV protease
- Evidence Grade:
- Preliminary evidence from structural biology providing detailed molecular insight into drug-target interactions, without in-vivo pharmacology data.
- Study Age:
- Published in 1999. Macrocyclic drug design has become a major pharmaceutical strategy, with several macrocyclic drugs now in clinical use for HIV and other diseases.
- Original Title:
- Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.
- Published In:
- Biochemistry, 38(25), 7978-88 (1999)
- Authors:
- Martin, J L, Begun, J, Schindeler, A, Wickramasinghe, W A, Alewood, D, Alewood, P F, Bergman, D A, Brinkworth, R I, Abbenante, G, March, D R, Reid, R C, Fairlie, D P
- Database ID:
- RPEP-00539
Evidence Hierarchy
Frequently Asked Questions
What is a macrocyclic peptidomimetic?
It's a ring-shaped molecule designed to mimic a peptide. Making a linear peptide circular can dramatically improve its stability and ability to cross cell membranes, making it a better drug candidate.
How does this help fight HIV?
HIV protease is essential for the virus to replicate. These macrocyclic inhibitors block the enzyme with improved stability over earlier linear peptide inhibitors, potentially leading to better anti-HIV drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00539APA
Martin, J L; Begun, J; Schindeler, A; Wickramasinghe, W A; Alewood, D; Alewood, P F; Bergman, D A; Brinkworth, R I; Abbenante, G; March, D R; Reid, R C; Fairlie, D P. (1999). Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.. Biochemistry, 38(25), 7978-88.
MLA
Martin, J L, et al. "Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.." Biochemistry, 1999.
RethinkPeptides
RethinkPeptides Research Database. "Molecular recognition of macrocyclic peptidomimetic inhibito..." RPEP-00539. Retrieved from https://rethinkpeptides.com/research/martin-1999-molecular-recognition-of-macrocyclic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.